Human Oncology & Pathogenesis Program

The Sarat Chandarlapaty Lab

Research

Sarat Chandarlapaty, MD, PhD
Sarat Chandarlapaty, MD, PhD
Naddisy Foundation Chair in Breast Cancer Research

The goal of our research program is to understand the detailed mechanisms by which a cancer cell can develop resistance to therapies targeting its oncogenic driver; and to exploit those findings to elucidate the biology of cancer and identify more effective treatments for cancer patients. The focus of this work has been on signaling networks emanating from the hormone receptor, ERa, and the receptor tyrosine kinase, HER2. These two signals play a dominant role in cancers of the breast, with roughly 85% of all tumors driven by one or both of these receptors. Whereas drugs targeting these signals have major benefits in patients, resistance to therapy is frequently encountered. Our studies have centered on (1) understanding how cancers evolve to resist therapies against ER, CDK4/6, HER2, and PI3K and (2) development of mechanism-based drugs or treatment strategies that can prevent or overcome these modes of resistance. 


 

 

View Lab Overview

Chandarlapaty Lab Team

People

Sarat Chandarlapaty, MD, PhD

Sarat Chandarlapaty, MD, PhD

Naddisy Foundation Chair in Breast Cancer Research

  • Physician-scientist Sarat Chandarlapaty studies the regulation of growth factor signaling networks in cancer.
  • PhD, University of North Carolina
[email protected]
Email Address
View physician profile
Physician profile

Members

Yanyan Cai

Senior Research Scientist

Wanyi Chen

WGS Student

Joshua Drago

Assistant Attending

Avantika Gupta
Avantika Gupta

Research Scholar

Minna Lee

Assistant Attending

Nicholas Mai
Samuel Molina

GSK Graduate Student

Sharanya Nag

Research Scholar

Payal Patel

Graduate Student

Hong Shao

Research Lab Manager

Allen Zhu

Research Technician

Lab Alumni
Trusha Bhatt
Trusha Bhatt

Research Technician

Isabella Del Priore
Isabella Del Priore

Research Technician

Madeline Dorso
Madeline Dorso

Graduate Student

Mayur Gadiya
Mayur Gadiya

Graduate Student

Kinisha Gala
Kinisha Gala

Project Owner, Larvol

Seema Irani
Seema Irani
Catherine Jones

Research Technician

Jisun Kim

Visiting Investigator

Rei Kudo
Rei Kudo

Research Fellow

Qing Li
Qing Li

Research Fellow

Zhiqiang Li
Zhiqiang Li

Research Fellow

Bo Liu, Research Associate
Bo Liu

Research Associate

Antonio Marra

Research Associate

Elizabeth O'Connell

Research Technician

Shraddha Pancholi
Shraddha Pancholi

Research Secretary

Ramya Segu Rajappachetty
Ramya Segu Rajappachetty

Research Technician Sr.

Alison Smith
Alison Smith

Graduate Student

Antonio Strillacci
Antonio Strillacci

Research Fellow

Weiyi Toy
Weiyi Toy

Research Fellow

Sharmeen Uddin
Sharmeen Uddin

Research Technician

Marie Will

Assistant Attending

ChengCheng Yang
ChengCheng Yang

Graduate Research Assistant

Lab Affiliations

Achievements

  • Professor of Medicine, Weill Cornell Medical College and Weill Cornell Cell and Developmental Biology Program
  • Member Memorial Sloan Kettering Cancer Center, Department of Medicine and Human Oncology and Pathogenesis Program

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Sarat Chandarlapaty discloses the following relationships and financial interests:

  • AstraZeneca
    Professional Services and Activities
  • Blueprint Medicines
    Professional Services and Activities
  • Casdin Capital, LLC
    Professional Services and Activities
  • Daiichi Sankyo
    Professional Services and Activities
  • eFFECTOR Therapeutics
    Equity; Professional Services and Activities
  • Eli Lilly and Company
    Professional Services and Activities (Uncompensated)
  • Encore Medical Education
    Professional Services and Activities
  • Genesis Therapeutics
    Professional Services and Activities
  • Gerson Lehrman Group
    Professional Services and Activities
  • Novartis
    Professional Services and Activities
  • Nuvalent, Inc.
    Professional Services and Activities
  • Odyssey Biosciences
    Equity; Fiduciary Role / Position; Intellectual Property Rights
  • Prelude Therapeutics
    Professional Services and Activities
  • SAGA Diagnostics
    Professional Services and Activities
  • Springer Nature Limited
    Professional Services and Activities
  • Totus Medicines Inc.
    Equity

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures